晚期年龄相关性黄斑变性临床研究中的影像学方案:萎缩分类共识会议的建议
该文为两次萎缩分类共识会议(CAM)的结果,由视网膜专家小组系统评估多种视网膜影像模态在晚期非新生血管性和新生血管性年龄相关性黄斑变性(AMD)中的优劣,建议采用多模态影像方案检测和量化萎缩,并给出各模态在自然史研究和干预性临床试验中的使用建议。
要点
- 检测、量化及监测萎缩进展的影像方案应包括彩色眼底照相、共聚焦眼底自发荧光、共聚焦近红外反射和高分辨率OCT容积扫描。
- 非新生血管性AMD研究中基线及研究终点访视彩色眼底照相可能已足够,任何访视时可能需要荧光素血管造影评估新生血管。
- 新生血管性AMD研究应纳入荧光素血管造影(推荐基线和选定随访访视)并在特定条件下考虑吲哚菁绿血管造影。
核心结论
- 建议在临床研究中采用多模态影像方案以最佳检测和测量萎缩及其相关特征。
- 需要专门的验证性研究来确定最佳影像模态组合,且随着未来新影像技术的出现,这些建议需要更新。
研究设计与样本
- 两次共识会议(萎缩分类会议,CAM)对多种影像模态相关性进行系统辩论,由视网膜专家小组基于大量临床病例的集体分析评估各模态优劣。
- 系统讨论各模态在未来非新生血管性和新生血管性AMD研究中的作用,主要结局指标为当前视网膜影像技术的优劣及在晚期AMD试验中的使用建议。
诊断标准与关键数值
- 检测、量化及监测萎缩进展的影像方案应包括彩色眼底照相、共聚焦眼底自发荧光、共聚焦近红外反射和高分辨率OCT容积扫描,并在整个研究期间定期采集。
- 非新生血管性AMD研究(基线无活动性或消退性新生血管明显征象)中,基线和研究终点访视彩色眼底照相可能已足够;研究期间任何访视可能需要荧光素血管造影评估新生血管;特定条件下基线可考虑吲哚菁绿血管造影。
- 新生血管性AMD研究中需考虑对血管可视化需求增加,应纳入荧光素血管造影(推荐基线和选定随访访视),并在特定条件下行吲哚菁绿血管造影。
临床应用与阅片要点
- 建议在临床研究中采用多模态影像方案以最佳检测和测量萎缩及其相关特征。
- 非新生血管性AMD研究中基线和研究终点访视彩色眼底照相可能已足够,任何访视可能需要荧光素血管造影评估新生血管。
- 新生血管性AMD研究应纳入荧光素血管造影(推荐基线和选定随访访视),特定条件下行吲哚菁绿血管造影。
局限性
- 需要专门的验证性研究来确定最佳影像模态组合。
- 这些建议需要随着未来新影像技术的出现而更新。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To summarize the results of 2 consensus meetings (Classification of Atrophy Meeting [CAM]) on conventional and advanced imaging modalities used to detect and quantify atrophy due to late-stage non-neovascular and neovascular age-related macular degeneration (AMD) and to provide recommendations on the use of these modalities in natural history studies and interventional clinical trials.
DESIGN: Systematic debate on the relevance of distinct imaging modalities held in 2 consensus meetings.
PARTICIPANTS: A panel of retina specialists.
METHODS: During the CAM, a consortium of international experts evaluated the advantages and disadvantages of various imaging modalities on the basis of the collective analysis of a large series of clinical cases. A systematic discussion on the role of each modality in future studies in non-neovascular and neovascular AMD was held.
MAIN OUTCOME MEASURES: Advantages and disadvantages of current retinal imaging technologies and recommendations for their use in advanced AMD trials.
RESULTS: Imaging protocols to detect, quantify, and monitor progression of atrophy should include color fundus photography (CFP), confocal fundus autofluorescence (FAF), confocal near-infrared reflectance (NIR), and high-resolution optical coherence tomography volume scans. These images should be acquired at regular intervals throughout the study. In studies of non-neovascular AMD (without evident signs of active or regressed neovascularization [NV] at baseline), CFP may be sufficient at baseline and end-of-study visit. Fluorescein angiography (FA) may become necessary to evaluate for NV at any visit during the study. Indocyanine-green angiography (ICG-A) may be considered at baseline under certain conditions. For studies in patients with neovascular AMD, increased need for visualization of the vasculature must be taken into account. Accordingly, these studies should include FA (recommended at baseline and selected follow-up visits) and ICG-A under certain conditions.
CONCLUSIONS: A multimodal imaging approach is recommended in clinical studies for the optimal detection and measurement of atrophy and its associated features. Specific validation studies will be necessary to determine the best combination of imaging modalities, and these recommendations will need to be updated as new imaging technologies become available in the future.
引用
- Holz FG, Sadda SR, Staurenghi G, et al. Imaging Protocols in Clinical Studies in Advanced Age-Related Macular Degeneration: Recommendations from Classification of Atrophy Consensus Meetings. Ophthalmology. 2017. PMID: 28109563. doi:10.1016/j.ophtha.2016.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。